Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.46 EUR | -0.36% | -0.36% | -2.06% |
May. 09 | Mib bearish; focus on quarterly reports and BoE | AN |
May. 08 | Milan lone in red; Leonardo tops Mib | AN |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.06% | 1.03B | B | ||
+9.48% | 27.43B | B+ | ||
-28.65% | 3.18B | B- | ||
-16.08% | 2.53B | C+ | ||
+19.05% | 2.49B | - | A- | |
+11.11% | 2.16B | B | ||
-4.24% | 2.03B | - | ||
+1.69% | 1.31B | - | ||
+29.73% | 1.29B | C | ||
+8.01% | 1.17B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GVS Stock
- Ratings GVS S.p.A.